FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 31951 - Risk Communication Advisory Committee - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	Risk Communication Advisory Committee	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	31951
Original Establishment Date	7/17/2009	Committee Status	Administratively Inactive
Actual Termination Date		Committee URL	http://www.fda.gov/AdvisoryCommittees/Committee...
Actual Merged Date		Presidential Appointments*	No
New Committee This FY	No	Max Number of Members*	15
Terminated This FY	No	Designated Fed Officer Position Title*	DFO
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	7/17/2009	Designated Federal Officer First Name*	Ashlee
Date Of Renewal Charter		Designated Federal Officer Middle Name	N
Projected Termination Date		Designated Federal Officer Last Name*	Janusziewicz
Exempt From Renewal*	Yes	Designated Federal Officer Suffix
Specific Termination Authority		Designated Federal Officer Phone*	(301) 796-7614
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*	301-847-3640
Specific Establishment Authority*	21 U.S.C. 360bbb-6	Designated Federal Officer Email*	ashlee.janusziewicz@fda.hhs.gov
Effective Date Of Authority*	9/27/2007
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Scientific Technical Program Advisory Board

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Terminate
Legislation to Terminate Required	Yes
Legislation Status	Pending
How does cmte accomplish its purpose?*	Members' comments and discussion provide advice to the Agency on improving communications practices, from both a basis of scientific research and practical experience, in matters ranging from specific types of agency communications to more general strategies and research needs, in order to help the agency accomplish its goal of improving patient and consumer safety by providing risk-benefit information that is clear, timely, and usable by the audience. The meetings also facilitate the RCAC purpose of interactive sharing of information between the FDA and the public.
How is membership balanced?*	The RCAC consists of 15 voting members including the Chair. Members are selected among authorities in fields such as risk communication, social marketing, health literacy, and other relevant areas. Some members will be selected to provide experiential insight on the communications needs of various groups who use FDA-regulated products such as patients, healthcare professionals, consumer or patient advocacy organizations. Depending on the topic, the commissioner or designee may select from a group of individuals nominated by industry to serve temporarily as nonvoting members who are identified with industry interests. FDA will give close attention to distribution with respect to members' geographic region, minority status, and sex, so long as the effectiveness of the Committee is not impaired.
How frequent & relevant are cmte mtgs?*	The committee is considered Administrative Inactive.
Why advice can't be obtained elsewhere?*	FDA strives to communicate with many audiences using many instruments, but in the past not all were developed or evaluated in ways consistent with established best practices in risk communication. The RCAC is necessary in order to bring expertise on current research and established best practices to the Agency, to help the agency interact with the public for more effective risk communication. This need was recognized both in the Congress (HR 3580) and the National Academies' Institute of Medicine (The Future of Drug Safety, recommendation 6.1).
Why close or partially close meetings?	N/A
Recommendation Remarks	This committee is Administratively Inactive as the committee has completed the work that was required by the originating statute.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	Yes	Action Reallocate Resources	No
Outcome Major Policy Changes	Yes	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	No	Action Approved Grants Or Other Payments	No
Outcome Improved Service Delivery	No	Action Other	Yes
Outcome Increased Customer Satisfaction	Yes	Action Comment	The committee does not advise on resource allocation, but prioritization may be reflected in resource allocation. The other actions boxes above that are checked applicable are showing that the Agency is actively engaged in developing internal strategy, process, and capacity to implement recommendations more fully, but none of this is complete at this time. The boxes above that are blank are, to date, inapplicable.
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	No
Outcome Other	No	Number Of Grants Reviewed	0
Outcome Comment	N/A	Number Of Grants Recommended	0
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$0.00
Cost Savings Comment	The utilization of the Risk Communication Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical, scientific and communications experts not otherwise available to the Agency and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.	Grants Review Comment	N/A
Number Of Recommendations*	188	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	The committee made 188 recommendations from FY03 through FY21.	Access Agency Website	Yes
% of Recs Fully Implemented*	20.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	70.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.	Access Other	No
Agency Feedback*	Yes	Access Comment	N/A
Agency Feedback Comment*	Feedback is usually provided. When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.	Narrative Description*	FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Risk Communication Advisory Committee supports FDA's strategic priorities by providing expert advice on FDA strategies and programs designed to communicate with the public about the risks and benefits of FDA-regulated products, review and evaluate scientific research relevant to risk communication, and facilitate the interactive sharing between FDA and the public of information on risks and benefits of FDA-regulated products.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 10:00 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Communications Broadcasting and Communications Health Public Health Safety Social Sciences Risk Communication Social Sciences

Custom Links

Committee Level Reports